Lucia Pinto-Gonzalez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.

In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.

Journal: Antimicrobial agents and chemotherapy

Published: August 19, 2026

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.

Journal: Antimicrobial agents and chemotherapy

Published: May 29, 2026

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.

Journal: Antimicrobial agents and chemotherapy

Published: May 29, 2026

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.

Journal: Antimicrobial agents and chemotherapy

Published: March 27, 2026

Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).

Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).

Journal: Antimicrobial agents and chemotherapy

Published: February 19, 2026

Emergence of New Delhi Metallo-β-Lactamase 14-Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands.

Emergence of New Delhi Metallo-β-Lactamase 14-Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands.

Journal: Emerging infectious diseases

Published: January 30, 2026

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants.

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants.

Journal: Antimicrobial agents and chemotherapy

Published: December 22, 2025

Molecular epidemiology of OXA-1054, a novel carbapenem-hydrolysing Class D β-lactamase, in Enterobacteriaceae isolated from wastewaters.

Molecular epidemiology of OXA-1054, a novel carbapenem-hydrolysing Class D β-lactamase, in Enterobacteriaceae isolated from wastewaters.

Journal: npj antimicrobials and resistance

Published: December 03, 2025

In vitro susceptibility testing of cefiderocol in different media of Mueller-Hinton agar.

In vitro susceptibility testing of cefiderocol in different media of Mueller-Hinton agar.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: October 23, 2025

Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.

Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.

Journal: Antimicrobial agents and chemotherapy

Published: October 21, 2025

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.

Journal: Antimicrobial agents and chemotherapy

Published: July 25, 2025

Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa.

Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa.

Journal: Antimicrobial agents and chemotherapy

Published: May 27, 2025

Showing 1-12 of 26

Last Updated: 09/26/2026